Statins and Breast Cancer: May Matrix Metalloproteinase be the Missing Link

REFERENCES

• Sanchez C. A., Rodriguez E., Varela E., Zapata E., Páez A., Massó F. A., Montaño L. F., Lóopez-Marure R. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 2008; 26: 698–707
   PubMed Web of Science ®Google Scholar
• Sassano A., Platanias L. C. Statins in tumor suppression. Cancer Lett. 2008; 260: 11–19
   PubMed Web of Science ®Google Scholar
• Mannello F., Tonti G. A., Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005; 5: 285–298
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C., Matrisian L. M. Emerging roles of proteases in tumour suppression. Nature Rev Cancer 2007; 7: 800–808
   PubMed Web of Science ®Google Scholar
• Martin M. D., Matrisian M. L. The other side of MMPs: protective roles in tumor progression. Cancer Metastases Rev. 2007; 26: 717–724
   PubMed Web of Science ®Google Scholar
• Chabottaux V., Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007; 24: 647–656
   PubMed Web of Science ®Google Scholar
• Goldstein M. R., Mascitelli L., Pezzetta F. Cholesterol, statins, and mortality. Lancet 2008; 371: 1161
   PubMedGoogle Scholar
• Browing D. R., Martin R. M. Statins and risk of cancer: a systematic review and meta-analysis. Int J. Cancer 2008; 120: 833–843
   Web of Science ®Google Scholar
• Taylor M. L., Wells B. J., Smolak M. J. Statins and cancer: a meta-analysis of case-control studies. Eur J. Cancer Prev. 2008; 17: 259–268
   PubMed Web of Science ®Google Scholar
• Solomon K. R., Freeman M. R. Do the cholesterol-lowering properties of statins affect cancer risk?. Trends Endocr Metab. 2008; 19: 113–121
   PubMed Web of Science ®Google Scholar
• Wang I. K., Lin-Shiau S. Y., Lin J. K. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 2000; 59: 245–254
   PubMed Web of Science ®Google Scholar
• Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi-Khorassani T., Vannier J. P., Soria J., Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001; 495: 159–166
   PubMed Web of Science ®Google Scholar
• Denoyelle C., Albanese P., Uzan G., Hong L., Vannier J. P., Soria J., Soria C. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-Coa reductase, on aggressive human breast cancer cells. Cell Signal 2003; 15: 327–338
   PubMed Web of Science ®Google Scholar
• Thunyakitpisal P. D., Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci. 2004; 94: 403–409
   PubMed Web of Science ®Google Scholar
• Taras D., Blanc J. F., Rullier A., Dugot-Senant N., Laurendeau I., Vidaud M., Rosenbaum J. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol. 2007; 46: 69–76
   PubMed Web of Science ®Google Scholar
• Gauthaman K., Richards M., Wong J., Bongso A. Comparative evaluation of the effects of statins on human stem and cancer cells in vitro. Reprod Biomed Online 2007; 15: 566–581
   PubMed Web of Science ®Google Scholar
• Mannello F., Tonti G. A., Bagnara G. P., Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 2007; 24: 475–481
   Web of Science ®Google Scholar
• Wang C. Y., Liu P. Y., Liao J. K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008; 14: 37–44
   PubMed Web of Science ®Google Scholar
• Vickers S., Duncan C. A., Vyas K. P., Kari P. H., Arison B., Prakash S. R., Ramjit H. G., Pitzenberger S. M., Stokker G., Duggan D. E. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG-CoA reductase. Drug Metab Dispos. 1990; 18: 476–483
   PubMed Web of Science ®Google Scholar
• Halpin R. A., Ulm E. H., Till A. E., Kari P. H., Vyas K. P., Hunninghake D. B., Duggan D. E. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos. 1993; 21: 1003–1011
   PubMed Web of Science ®Google Scholar
• Kieseier B. C., Archelos J. J., Hartung H. P. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol. 2004; 61: 929–932
   PubMed Web of Science ®Google Scholar
• Neuhaus O., Strasser-fuchs S., Fazekas F., Kieseier B. C., Niederwieser G., Hartung H. P., Archelos J. J. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002; 59: 990–997
   PubMed Web of Science ®Google Scholar
• Turner N. A., O'Regan D. J., Ball S. G., Porter K. E. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 2005; 19: 804–806
   PubMed Web of Science ®Google Scholar
• Li M., Li Z., Sun X. Statins suppress MMP-2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscle cells. Eur J. Pharmacol. 2008; 591: 219–223
   PubMed Web of Science ®Google Scholar
• Kumar A. S., Benz C. C., Shim V., Minami C. A., Moore D. H., Esserman L. J. Estrogen receptor-negative breast cancer is less likely arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1028–1033
   PubMed Web of Science ®Google Scholar
• Kwan M. L., Habel L. A., Flick E. D., Quesenberry C. P., Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008; 109: 573–579
   PubMed Web of Science ®Google Scholar
• Byers T. Statins, breast cancer, and an invisible switch?. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1026–1027
   PubMed Web of Science ®Google Scholar
• Cariati M., Purushotham A. D. Stem cells and breast cancer. Histopathology 2008; 52: 99–107
   PubMed Web of Science ®Google Scholar
• Sotgia F., Rui H., Bonuccelli G., Mercier I., Pestell R. G., Lisanti M. P. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res. 2006; 66: 10647–10651
   Google Scholar
• Elsheikh S. E., Green A. R., Rakha E. A., Samaka R. M., Ammar A. A., Powe D., Reis-Filho J. S., Ellis I. O. Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple negative immunophenotype. Br J. Cancer 2008; 99: 327–334
   PubMed Web of Science ®Google Scholar
• Schlegel A., Lisanti M. P. The caveolin triad: caveolae biogenesis, cholesterol trafficking, and signal transduction. Cytokine Growth Factor Rev. 2001; 12: 41–51
   PubMed Web of Science ®Google Scholar
• Williams T. M., Sotgia F., Lee H., Hassan G., Di Vizio D., Bonuccelli G., Capozza F., Mercier I., Rui H., Pestell R. G., Lisanti M.P. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J. Pathol. 2006; 169: 1784–1801
   PubMed Web of Science ®Google Scholar
• Sloan E. K., Stanley K. L., Anderson R. L. Caveolin-1 inhibits breast cancer growth and metastases. Oncogene 2004; 23: 7893–7897
   PubMed Web of Science ®Google Scholar
• Williams T. M., Medina F., Badano I., Hazan R. B., Hutchinson J., Muller W. J., Chopra N. G., Scherer P. E., Pestell R. G., Lisanti M. P. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastases in vivo. Role of cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279: 51630–51646
   PubMed Web of Science ®Google Scholar
• Plenz G. A.M., Hofnagel O., Robenek H. Differential modulation of caveolin-1 expression in cells of the vasculature by statins. Circulation 2004; 109: e7–e8
   PubMed Web of Science ®Google Scholar
• Bonovas S., Filioussi K., Tsavaris N., Sitaras N. M. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005; 23: 8606–8612
   PubMed Web of Science ®Google Scholar
• Boudreau D. M., Yu O., Miglioretti D. L., Buist D. S., Heckbert S. R., Daling J. R. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarker Prev. 2007; 16: 416–421
   PubMed Web of Science ®Google Scholar
• Pocobelli G., Newcomb P. A., Trentham-Dietz A., Titus-Ernstoff L., Hampton J. M., Egan K. M. Statin use and risk of breast cancer. Cancer 2008; 112: 27–33
   PubMed Web of Science ®Google Scholar
• Cauley J. A., McTiernan A., Rodabough R. J., LaCroix A., Bauer D. C., Margolis K. L., Paskett E. D., Vitolins M. Z., Furberg C. D., Chlebowski R. T. Women's Health Initiative Research Group. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006; 98: 700–707
   PubMed Web of Science ®Google Scholar
• King B. L., Love S. M. The intraductal approach to breast cancer: raison d'etre. Breast Cancer Res. 2006; 8: 206
   PubMedGoogle Scholar
• Dua R. S., Isacke C. M., Gui J. P. The intraductal approach to breast cancer biomarker discovery. J Clin Oncol. 2006; 24: 1209–1216
   PubMed Web of Science ®Google Scholar
• Mannello F., Tonti G. A., Canestari F. Nutrients and nipple aspirate fluid composition: the breast microenvironment regulates protein expression and cancer etiology. Genes Nutr. 2008; 3: 77–85
   PubMed Web of Science ®Google Scholar
• Mannello F., Qin W., Zhu W., Fabbri L., Tonti G. A., Sauter E. R. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2. Breast Cancer Res Treat 2008; 111: 209–218
   PubMed Web of Science ®Google Scholar
• Duncan R.E., El-Sohemy A., Arker M. C. Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl Coenzyme A reductase: implications for breast cancer and development. Mol Nutr Food Res. 2005; 49: 93–100
   PubMed Web of Science ®Google Scholar
• Kuoppala J., Lamminpaa A., Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J. Cancer 2008, (doi: 10.1016/j.ejca.2008.06.025)
   PubMedGoogle Scholar